| Article | Added |
|---|
| Karyopharm grabs $48M round for pipeline work | 05-20-13 |
| FDA bestows 'Breakthrough Therapy' status to drug for fatal infant disease | 05-20-13 |
| Pentagon adviser quietly pocketed biotech's cash while promoting its interests | 05-20-13 |
| FDA: Merck's sleep drug suvorexant effective, but safety issues draw heavy flak | 05-20-13 |
| XenoPort shares skid after MS drug proves to be a lemon in PhIII | 05-20-13 |
| Elan orchestrates $693M biotech buyout, $90M spinout in deal frenzy | 05-20-13 |
| Effector Therapeutics snags $45M venture round from A-list backers | 05-20-13 |
| AbbVie, Galapagos extend JAK1 pact into Crohn's disease with $50M carrot | 05-17-13 |
| Third Rock Ventures adds biotech veterans to team | 05-17-13 |
| Novo Nordisk completes PhIII hemophilia trial with positive results | 05-17-13 |
| Pain Therapeutics, Durect shares nosedive on haziness for Pfizer's Remoxy | 05-10-13 |
| Anna Protopapas replaces Deborah Dunsire as Millennium oncology head | 05-10-13 |
| Eli Lilly jettisons cancer contender after another Phase III failure | 05-10-13 |
| Biotech VC firm Frazier Healthcare closes in on $300M fund | 05-10-13 |
| Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups | 05-10-13 |
| Deborah Dunsire exits as Takeda cuts CEO role in Millennium shakeup | 05-09-13 |
| U.S. drug market shrinks for first time | 05-09-13 |
| FDA's Hamburg touts rising approval record and promises swifter interaction | 05-09-13 |
| Biotech Receptos claims $73M IPO prize to fuel oral MS contender | 05-09-13 |
| CytRx dumps failed IIb trial for lung cancer, focuses on aldoxorubicin | 05-09-13 |
| Global CRO Quintiles rakes in $947M as its hot IPO sells at top range | 05-09-13 |
| Trevena lands $430M Forest deal, $60M venture round as heart drug heads to PhIIb | 05-09-13 |
| Fast-growing Biogen Idec bursts the seams at new Cambridge HQ | 05-08-13 |
| The pharma spin-offs have just begun | 05-08-13 |
| Shire strikes discovery deal in rare diseases with Bill Gates-backed Nimbus | 05-08-13 |
| China backs its booming biopharma industry with big subsidies | 05-08-13 |
| Which Big Biotechs are hitting the gas pedal on R&D spending? | 05-08-13 |
| Genomics, Biotechnology's Oldest Next Big Thing | 05-08-13 |
| Startup biotech charges into PhII with $23M bankroll for rare disease drugs | 05-08-13 |
| Takeda beefs up new vaccines arm with $250M bolt-on buyout of Inviragen | 05-08-13 |
| Biotech trio to take over Alderley labs as AstraZeneca heads south | 05-07-13 |
| GlaxoSmithKline's 'independent experts' start to hand out keys to its data vault | 05-07-13 |
| NGM raises $13M for cardio/metabolic R&D work | 05-07-13 |
| Astellas, VCs stake virtual biotech spinout with $15M and a PhII program | 05-07-13 |
| Baxter adds Gammagard to growing roster of Ph III Alzheimer's failures | 05-07-13 |
| Celgene nabs another round of promising pivotal apremalist data for psoriatic arthritis | 05-06-13 |
| Johnson & Johnson, Pfizer target painkiller revivals as FDA warms to abuse deterrents | 05-06-13 |
| NeuroPhage banks $6.4M for Alzheimer's drug development effort | 05-06-13 |
| Bristol-Myers, AstraZeneca report positive data for rare metabolic disease drug | 05-06-13 |
| AbbVie gains inside 'breakthrough' track at FDA for hot hep C combo | 05-06-13 |
| Novartis promises to test the full value of FDA's 'breakthrough' status | 05-06-13 |
| Celgene turns to Concert for $300M deuterium-tweaking cancer collaboration | 05-06-13 |
| Novartis probes controversy around Diovan studies | 05-03-13 |
| AltheRx Pharma adds $15M, new CEO and ex-AstraZeneca exec | 05-03-13 |
| Biotech financier Blech gets jail time in 'No mercy' sentence | 05-03-13 |
| Moderna taps biotech legend Henri Termeer for board of directors | 05-03-13 |
| Who Will Figure Out How to Make a Business Out of Fecal Transplants? | 05-03-13 |
| Sanofi lets go of rights to Regeneron's antibodies in ophthalmology | 05-03-13 |
| Bristol-Myers' 'smart bomb' deal pushes Ambrx 12-month deal tally to $715M | 05-03-13 |
| Arena shares sink after biotech withdraws marketing app for obesity drug in Europe | 05-03-13 |
| FDA panel rejects Aveo's kidney cancer drug tivozanib | 05-02-13 |
| Biotech Symphogen tacks on $53.7M to big venture round after Merck Serono deal | 05-02-13 |
| New Shire CEO Ornskov shakes up company after seizing the reins | 05-02-13 |
| Capital Royalty launches $805M fund for biotech, healthcare deals | 05-02-13 |
| Merck buddies up to Scripps spinout Abide in $430M diabetes partnership | 05-02-13 |
| Biogen CEO Scangos scores 19% pay hike during stellar 2012 | 05-01-13 |
| Billionaire Kirk grabs $150M round for synthetic biology deals at Intrexon | 05-01-13 |
| Allergan slams brakes on two key PhIIIs after data disappoints | 05-01-13 |
| J&J grabs another 'breakthrough' FDA win with early-stage cancer drug | 05-01-13 |
| Seaside Therapeutics fails to achieve main goal in major trial in autism | 05-01-13 |
| Atlas Venture targets early-stage biotech bets with new $265M fund | 05-01-13 |
| EMA vows to battle AbbVie in courts for full data transparency | 05-01-13 |
| Raptor's orphan drug-win at FDA overshadowed by debate over steep price | 05-01-13 |
| Merck spotlights new deals, R&D review as demands to rebuild pipeline grow | 05-01-13 |
| VCs provide $40M to finance Celator's pivotal PhIII AML study | 05-01-13 |
| FDA steamrolls over panel vote, spurns Titan's addiction drug Probuphine | 05-01-13 |
| Johnson & Johnson allies with biotech startup on HIV drug in China | 04-30-13 |
| Celladon's gene therapy for heart failure takes spotlight in the U.K. | 04-30-13 |
| Biotech legend Termeer joins the board at Moderna | 04-30-13 |
| Biotech upstart joins Big Pharma cast on high-profile 'breakthrough' stage | 04-30-13 |
| Aveo shares plunge after FDA raises fears of tivozanib rejection | 04-30-13 |
| Regado gambles on $75M IPO to pay pricey PhIII tab | 04-30-13 |
| GlaxoSmithKline throws in the towel on $186M Parkinson's pact with Impax | 04-29-13 |
| U.K. union makes its case against AstraZeneca's R&D relocation | 04-29-13 |
| FDA rejects two of the four drugs in Gilead's blockbuster HIV drug Stribild | 04-29-13 |
| Giants team on diabetes as Merck partners with Pfizer on SGLT2 combo | 04-29-13 |
| Celgene taps biotech Forma for drugs in hot field of protein homeostasis | 04-29-13 |
| MedImmune chief taps top prospects, hunts new biologics deals | 04-28-13 |
| Docs may find stellar Gilead/Bristol-Myers hep C combo too good to ignore | 04-28-13 |
| Guidelines for contributing an Industry Voices column to Fierce | 04-26-13 |
| Fierce at BIO 2013 in Chicago | 04-26-13 |
| Biotech Receptos trots out terms for $71M IPO | 04-26-13 |
| Biotech startup hustles new Alzheimer's program to the clinic | 04-26-13 |
| Johnson & Johnson, Evotec bask in Harvard's breaking diabetes discovery | 04-26-13 |
| Symonds Steps Down as Novartis CFO, Kirsch Takes Over | 04-26-13 |
| Industry Voices: Time to Take Fecal Transplantation Seriously | 04-26-13 |
| NIH stops HIV vaccine trial after immunizations fail | 04-26-13 |
| Europeans throw cold water on Pfizer's hot streak with Xeljanz rejection | 04-26-13 |
| Theravance to split into two companies | 04-25-13 |
| Bristol-Myers gains FDA's 'breakthrough' track in race for hep C drug approval | 04-25-13 |
| Radius nabs $43M round for PhIII bone-building drug | 04-25-13 |
| Eli Lilly slugs it out with J&J on Alzheimer's drug patent claim | 04-25-13 |
| Experienced biotech team snags $33M for promising PhII cholesterol drug | 04-25-13 |
| Acumen Pharma reveals A round closing to fund Alzheimer's drug research | 04-25-13 |
| AstraZeneca's PhIII chief scouts for blockbuster deals as revenue slides | 04-25-13 |
| Novartis changes CFOs, reveals cuts to workforce and chairman pay | 04-24-13 |
| Achaogen nails $60M in government funding to push antibiotics pipeline | 04-24-13 |
| French biotech Genticel lands $23.7M for 'blockbuster' HPV vaccine hopeful | 04-24-13 |
| Merck scores 'breakthrough' status from FDA for immunotherapy against melanoma | 04-24-13 |
| OPKO Health to acquire Prolor Biotech for $480M | 04-24-13 |
| AstraZeneca, Aussie biotech outfit ally in $240M-plus discovery deal | 04-24-13 |
| BIO: R&D execs say tweaks boost drug-development process | 04-23-13 |
| Roche restructuring will affect 170 jobs in Europe, U.S. | 04-23-13 |
| Chicago uses its turn in BIO spotlight to promote incubator plans | 04-23-13 |
| Moody's: Deep-pocketed pharma giants poised to boost M&A activity this year | 04-23-13 |
| Gilead keeps lead in hep C race after rivals post key trial results | 04-23-13 |
| E&Y: Biotech budget hawks rule the roost in year of mixed performance | 04-23-13 |
| GlaxoSmithKline and Avalon Ventures forge $495M biotech startup alliance | 04-22-13 |
| Updated: EU pharma CEOs earned 46% less than U.S. peers | 04-22-13 |
| Elan spurns buyout offer, preps for deal spree | 04-22-13 |
| The Top 15 Biotech VC firms | 04-22-13 |
| Bristol-Myers rebounds on hep C front with new Merck partnership | 04-22-13 |
| AstraZeneca works both sides of the Atlantic in forging new cancer drug deals | 04-22-13 |
| AstraZeneca and Boston biotech unite to blast cancer with a nanotech drug | 04-22-13 |
| India's clinical trial industry shrivels in wake of safety controversy | 04-21-13 |
| Merck peddles a pair of neuroscience programs to Baltimore biotech | 04-19-13 |
| Report: Don't count Celltrion out of Rituxan biosim race | 04-19-13 |
| Civitas Parkinson's drug improves motor fluctuations in Phase II trial | 04-19-13 |
| Pharma giants' oral EPO alternatives could cater to dopers | 04-19-13 |
| Hope to see you in Chicago for #BIO2013 | 04-19-13 |
| AEterna Zentaris brings on David Dodd as new CEO | 04-19-13 |
| Biotech rattled as Q1 first-time VC deals plunge to 18-year low | 04-19-13 |
| Vertex skyrockets on positive Ph2 combo study in cystic fibrosis | 04-18-13 |
| Epizyme hits the biotech IPO queue with rapid R&D plan for cancer drugs | 04-18-13 |
| FDA's Hamburg makes 'bargain' case in budget talks | 04-18-13 |
| Johnson & Johnson cashes out on Elan shares after failed Alzheimer's trials | 04-18-13 |
| Report: Antibiotics pipeline lackluster as resistance surges | 04-18-13 |
| Abbott aids biotech Epizyme in matching epigenetic drug with cancer patients | 04-18-13 |
| UPDATED: Roche sees another Rituxan biosimilar trial bite the dust | 04-18-13 |
| Antibiotics upstart Allecra snags ?15M VC round amid superbug scare | 04-18-13 |
| GlaxoSmithKline picks up FDA panel plug for Breo approval | 04-17-13 |
| Vivus clears one of many hurdles for new weight drug | 04-17-13 |
| Portola rolls out $115M IPO plan as more biotech outfits go public | 04-13-13 |
| Elan shareholders opt for $1B share buyback amid M&A talk | 04-12-13 |
| Pfizer to move hundreds of workers to heart of Boston-area R&D hub | 04-12-13 |
| Biotech Chimerix shines in IPO debut as interest grows in antiviral drugs | 04-12-13 |
| Firm ranks top 5 biotech deals in evolving pharma R&D landscape | 04-12-13 |
| Top IT chief Perakslis steps down at FDA | 04-12-13 |
| Boehringer Ingelheim fuels gene therapy startup focused on eye diseases | 04-12-13 |
| GlaxoSmithKline measures 38-meter leap over placebo in Duchenne walking test | 04-11-13 |
| Syros Pharma snags $30M funding deal to target master switches of cancer genes | 04-11-13 |
| Bristol-Myers maps $250M manufacturing expansion to support growing R&D effort | 04-11-13 |
| FierceBiotech hits the road | 04-11-13 |
| Omthera discounts IPO shares, prices at $8 | 04-11-13 |
| Acadia soars as FDA green-lights a late-stage shortcut for Parkinson's drug | 04-11-13 |
| NEA, Pfizer build a launch pad for a portfolio of orphan-drug biotechs | 04-11-13 |
| GlaxoSmithKline stakes a pioneering effort to launch "electroceutical" R&D | 04-10-13 |
| Genentech steps into spotlight with closely-watched cancer immunotherapy | 04-10-13 |
| VistaGen raises $36M for stem cell tech | 04-10-13 |
| Analysts rank the top 10 blockbuster duds in biopharma | 04-10-13 |
| FDA stokes blockbuster hopes with 'breakthrough' brand for Pfizer cancer drug | 04-10-13 |
| Amid cheers and jeers, GlaxoSmithKline reveals Duchenne drug hit primary PhII goal | 04-10-13 |
| Novartis ponders its option to acquire biotech Proteon in $550M deal | 04-10-13 |
| GlaxoSmithKline inks 5-year R&D pact with A*STAR | 04-09-13 |
| Groton throws up a new hurdle to Pfizer's R&D demolition plan | 04-09-13 |
| Lundbeck touts promising head-to-head data on depression drug Brintellix | 04-09-13 |
| Bristol-Myers' new R&D chief lays out PhIII game plan | 04-09-13 |
| NEA provides $10M to help fuel next-gen cancer R&D at Cleave | 04-09-13 |
| Gilead quickly asks FDA for blockbuster hep C approval | 04-08-13 |
| One-two vaccine punch against ovarian cancer takes center stage at AACR | 04-08-13 |
| Struggling Unigene slashes staff in reorganization | 04-08-13 |
| Investigator says 'insane' rules are blocking his study on magic mushrooms | 04-08-13 |
| Roche rolls out $392M Isis pact in two-pronged attack on Huntington's | 04-08-13 |
| Pharmacyclics bounces higher as J&J wins third 'breakthrough' cancer drug coup | 04-08-13 |
| In Sunday surprise, Bristol-Myers' R&D chief replaced by lieutenant | 04-08-13 |
| Blue chip venture groups arm gene therapy upstart with $41M launch round | 04-08-13 |
| Ex-Tokai CEO follows tau pathway to Alzheimer's upstart | 04-05-13 |
| Receptos hits biotech IPO queue with oral MS contender | 04-05-13 |
| Vertex, Bristol-Myers mix pills for Phase II study in hepatitis C | 04-05-13 |
| Rib-X taps former Abbott exec as new CEO | 04-05-13 |
| Sarepta sustains high hopes for DMD drug eteplirsen with more PhII data | 04-05-13 |
| AstraZeneca reports hit-and-miss PhIII for arthritis pill | 04-05-13 |
| Astellas, Ambrx seal $300M cancer ADC deal | 04-05-13 |
| Biogen Idec shares surge on positive multiple sclerosis drug data | 04-04-13 |
| Booming Regeneron to hire 400 staffers in big R&D expansion | 04-04-13 |
| Merrimack's lead lung cancer drug flunks first of three PhII tests | 04-04-13 |
| Can Merck use animal data to make its case against Lunesta, Ambien? | 04-04-13 |
| Fierce's 10 top biotech billionaires | 04-04-13 |
| Bristol-Myers shuttering Amylin's San Diego HQ, laying off hundreds | 04-04-13 |
| Celgene-backed Agios and Foundation partner in breakthrough cancer strategy | 04-04-13 |
| Langer startup Taris tracks down $12.5M round for drug-device combo | 04-03-13 |
| Novavax jumps on positive PhII for RSV vaccine | 04-03-13 |
| J&J, Pfizer chip in on $18M round for anti-inflammatory biotech's PhII | 04-03-13 |
| Biotech gamblers crowd high-stakes game for Sarepta | 04-03-13 |
| Elan closes $3.25B Tysabri deal and preps for biotech deal spree | 04-03-13 |
| AstraZeneca gambles on cardio therapy in AlphaCore buyout | 04-03-13 |
| Resurgent Pfizer partners with Bind on new nanotech drug effort | 04-03-13 |
| FierceBiotech believes in storytelling: Check it out | 04-02-13 |
| Chimerix, Omthera enter price ranges for expected biotech IPOs | 04-02-13 |
| Clavis preps endgame after final PhIII cancer drug failure | 04-02-13 |
| Next-gen Botox developer Revance raises $33M to wrap PhIII effort | 04-02-13 |
| Karolinska portfolio biotech says PhII lung cancer drug on promising track | 04-02-13 |
| Analysis: No quick fix in sight for AstraZeneca's PhIII woes | 04-02-13 |
| Obama seeks revolutionary brain discoveries on a budget | 04-02-13 |
| PolyMedix defaults and hands over a PhII antibiotic to bankruptcy court | 04-02-13 |
| Daiichi Sankyo ditches cancer drug program from ArQule | 04-01-13 |
| Clavis explores its options after second decisive PhIII cancer drug failure | 04-01-13 |
| Biotech M&A deals dominate key Q1 metric | 04-01-13 |
| BioCryst's shares spike on hope that flu drug can rise from the grave | 04-01-13 |
| New math on biosimilars sends a chilling message to Lonza/Teva team | 04-01-13 |
| Clashing stands of India, U.K. on drug patents, R&D will offer clear lessons | 04-01-13 |
| UPDATED: J&J wins first FDA approval for diabetes drug | 03-29-13 |
| Dainippon Sumitomo inks $545M-plus orphan drug R&D pact with Edison | 03-28-13 |
| Spotlight shines on injected RNA drug against hepatitis C amid pills-only frenzy | 03-28-13 |
| Connecticut pols stunned as Pfizer brings in the wrecking ball | 03-28-13 |
| Lobbyist Melissa A. Schulman Joins GPhA Government Affairs | 03-28-13 |
| Join the R&D revolution now | 03-28-13 |
| With big RNA deal, AstraZeneca's Soriot signals yen for risky science | 03-28-13 |
| Repros shares boom on promising PhIII results for testosterone drug | 03-28-13 |
| A.P. Pharma slapped with another FDA rejection on chemo drug | 03-28-13 |
| Biogen Idec rolls up FDA OK for blockbuster MS drug Tecfidera | 03-27-13 |
| Physicians in frenzy over slight positive benefit seen in chelation study | 03-27-13 |
| Acceleron wins orphan status for ACE-536 | 03-27-13 |
| What's in a cancer drug name? Maybe a $1.5M cash windfall for researchers | 03-27-13 |
| Little-known Reviva attracts a big angel crowd for $12M CNS round | 03-27-13 |
| Blessed by Gates, crowdfunding site funnels cash for high-risk R&D | 03-27-13 |
| Aastrom sinks after biotech flushes PhIII study for cardio therapy, halves staff | 03-27-13 |
| Sarepta's high-noon decision on eteplirsen draws a big biotech crowd | 03-27-13 |
| BioDelivery snaps up mid-stage diabetic pain drug in potential $39.5M-plus pact | 03-26-13 |
| GlaxoSmithKline gets green light for $91M vaccine facility | 03-26-13 |
| Phytopharm slashes staff, scouts buyers after Parkinson's drug failure | 03-26-13 |
| PRACS' CRO implosion leaves a Who's Who of biopharma creditors in its wake | 03-26-13 |
| Headed into PhIII, Lundbeck scores $825M Alzheimer's drug pact with Otsuka | 03-26-13 |
| Ziopharm sharpens budget ax after cancer drug palifosfamide flops in PhIII | 03-26-13 |
| Theraclone adds $14M to fuel antibody pipeline work | 03-25-13 |
| Trius targets key approvals after antibiotic matches Zyvox (again) in Phase III | 03-25-13 |
| Versant adds $7.5M to upstart biotech's A round | 03-25-13 |
| UPDATED: Shire buyout spree adds $160M deal for SARcode's PhIII eye drug | 03-25-13 |
| UPDATED: Third Rock Ventures adds $516M fund to back new portfolio of biotechs | 03-25-13 |
| Strike two: FDA hands United Therapeutics another rejection on oral Remodulin | 03-25-13 |
| Novartis snags FDA approval for antibiotic in CF patients | 03-23-13 |
| Biotechs beat generics rivals in state biosimilars battle | 03-22-13 |
| Europe gives thumbs down to Sanofi's cholesterol drug mipomersen | 03-22-13 |
| Biogen Idec, Sanofi secure European nods for blockbuster MS hopefuls | 03-22-13 |
| Amid more job cuts, AZ brings on GSK's Dunoyer as business chief | 03-22-13 |
| Cerulean Pharma's lead nanodrug crashes in lung cancer study | 03-22-13 |
| Titan claims victory for anti-addiction drug after mixed FDA panel votes | 03-22-13 |
| Report: CRO with a scandal-plagued past shuts down, leaving patients stranded | 03-21-13 |
| Genzyme boasts of durable response to MS drug Lemtrada | 03-21-13 |
| Bullish Acadia surges on PhIII data for Parkinson's drug | 03-21-13 |
| Teva touts fresh PhIII evidence of oral MS drug's potential | 03-21-13 |
| Enanta prices IPO shares at low end of range | 03-21-13 |
| GlaxoSmithKline reports another batch of weak results for malaria jab | 03-21-13 |
| Gene therapy combats acute leukemia in small study | 03-21-13 |
| Celgene makes big splash in gene therapy with two cancer collaborations | 03-21-13 |
| AstraZeneca chops 2,300 more jobs, narrows R&D focus and adds $420M-plus RNA deal | 03-21-13 |
| Biogen Idec advances blockbuster MS franchise on two key fronts | 03-20-13 |
| Aratana joins biotech IPO queue while Tetraphase takes a haircut | 03-20-13 |
| Volatile BioLineRx shares decimated by PhII/III schizophrenia drug failure | 03-20-13 |
| AstraZeneca feels sting of union backlash against R&D upheaval | 03-20-13 |
| Lone Star biotech banks $11.4M for PhII orphan drug odyssey | 03-20-13 |
| Amgen scores PhIII success with BioVex virus against melanoma | 03-20-13 |
| Omontys recall forces Affymax to ax 75% of workforce, weigh bankruptcy | 03-19-13 |
| FDA raises red flag for Pharmaxis' Bronchitol | 03-19-13 |
| Enanta pins $73M IPO bid on a hot hep C blockbuster contender | 03-19-13 |
| One foot in biotech graveyard, NeuroSearch is calling it quits | 03-19-13 |
| FDA staff review raises big questions about fate of Titan's Probuphine | 03-19-13 |
| NPS Pharma goes global with $80M deal to buy back Gattex rights | 03-19-13 |
| Incubator finds $30M in atypical biotech territory | 03-18-13 |
| Flush with cash, Onyx Pharma shops for new drugs | 03-18-13 |
| Vivus hopes weight-loss app will fatten up Qsymia sales | 03-18-13 |
| FDA's Hamburg warns of biotech fallout as sequester debate drags on | 03-18-13 |
| FDA readies final decisions on four big biotech drugs | 03-18-13 |
| UPDATED: AstraZeneca axes more staffers, relocates thousands in global R&D reshuffle | 03-18-13 |
| Biopharma's Top R&D Spenders - 2012 | 03-18-13 |
| Genomics player Illumina whacked with hefty patent case loss | 03-15-13 |
| Seattle biotech Allozyne suffers workforce woes | 03-15-13 |
| Merck hit with delay on FDA review of top drug prospect | 03-15-13 |
| Chimerix picks up Michael Rogers, unveils $85M IPO plan | 03-15-13 |
| Biotech startup Avitide attracts venture funding from familiar VC crowd | 03-15-13 |
| Novartis grabs FDA's coveted 'breakthrough' status for lung cancer drug | 03-15-13 |
| Biotech Chimerix reveals ex-Pharmasset recruit after unveiling $85M IPO plan | 03-14-13 |
| Nabsys Secures $20 Million Series D Financing to Support Launch of Semiconductor-Based Single-Molecule Platform for Genomic Analysis | 03-14-13 |
| Mesoblast raises $175M for PhIII stem cell study | 03-14-13 |
| Sinovac shares soar on success of PhIII EV71 vaccine in China | 03-14-13 |
| Navidea drops after FDA nod for drug used in cancer patients | 03-14-13 |
| Researchers, biopharma companies protest budget cuts at FDA, NIH | 03-14-13 |
| Presidio rebounds with Boehringer hep C cocktail collaboration | 03-14-13 |
| FDA proposes to dramatically lower the bar on Alzheimer's drugs | 03-14-13 |
| Cytos Biotechnology soars on results of asthma-drug study | 03-13-13 |
| AbbVie spins out a PhII orphan drug to Receptos--with a hook attached | 03-13-13 |
| Rogue Aptuit researcher convicted of manipulating Roche, AstraZeneca studies | 03-13-13 |
| Merck recruits Luminex for Alzheimer's diagnostics | 03-13-13 |
| Takeda taps Scripps as the pharma extends early-stage pipeline | 03-13-13 |
| J&J opens new innovation center in quest for more early-stage deals | 03-13-13 |
| Domain opens shop in China with plans to seed biotech startups, do deals | 03-13-13 |
| Will biotech grow in China and India without much VC help? | 03-12-13 |
| BREAKING: GSK moves to shutter Sirtris's Cambridge office, integrate R&D | 03-12-13 |
| Pharmaxis gets new CEO in shakeup | 03-12-13 |
| Small biotech in the spotlight after drug boosts memory in Alzheimer's study | 03-12-13 |
| Omthera files $75M IPO as it blueprints omega-3 drug launch | 03-12-13 |
| Analysts cheer decision to continue Merck's controversial Vytorin study | 03-12-13 |
| Puma Biotech shares roaring up amid M&A meow | 03-12-13 |
| Apprentice Shire CEO nabs a PhII rare disease drug in latest buyout | 03-12-13 |
| Astellas dumps $390M pact with Ambit on eve of IPO | 03-12-13 |
| Sanford-Burnham, Mayo hunt for drugs against high-priority targets | 03-11-13 |
| Roche touts upbeat PhII results for heart drug | 03-11-13 |
| Aeterna craters after researchers slam brakes on another failed perifosine PhIII | 03-11-13 |
| Cubist Pharma buys out antibiotic partner Astellas for $25M-plus | 03-11-13 |
| Leading industry backlash, AbbVie counterattacks on move to unlock Humira data | 03-11-13 |
| U.K. Catalyst fund injects $70M into new generation of biotechs | 03-11-13 |
| Medicines Co.'s blood thinner finally reaps positive results in third PhIII | 03-11-13 |
| Roche dumps fibrosis alliance with Belgian biotech | 03-08-13 |
| Diehard cancer vaccine developer files for bankruptcy with plans to emerge | 03-08-13 |
| Roche chairman steps down | 03-08-13 |
| Scientist spotlights potential Achilles heel of therapeutic cancer vaccines | 03-08-13 |
| Failed ALS study haunts Biogen in lawsuit from unhappy partner | 03-08-13 |
| Biotech PTC reloads coffers with $60M for late-stage DMD drug | 03-08-13 |
| Sirtris co-founder fires back against resveratrol critics | 03-07-13 |
| GSK's R&D chief outperforms CEO on pay | 03-07-13 |
| RXi snags OPKO's RNAi portfolio in penny stock swap | 03-07-13 |
| Aastrom lands a new CEO in a game of musical biotech chairs | 03-07-13 |
| GSK files diabetes drug in Europe in big regulatory offensive | 03-07-13 |
| Analysts track a spike in mid-cap biotechs' R&D spend | 03-07-13 |
| Ex-Amgen research czar Perlmutter to helm Merck's struggling R&D ops | 03-07-13 |
| Tesaro pockets $91M in big financing as major cancer trials continue | 03-06-13 |
| Analyst makes a dramatic apology, abandons last line of Dendreon defense | 03-06-13 |
| Royalty Pharma plans to press $6.6B Elan offer on investors | 03-06-13 |
| Japan's Ajinomoto pounces on Althea Tech in $175M buyout deal | 03-06-13 |
| TauRx adds $10.5M to its trove of unconventional Alzheimer's PhIII cash | 03-06-13 |
| Teva retrenches on troubled MS blockbuster hopeful as partner grabs $43M | 03-06-13 |
| Antibiotics outfit Tetraphase offers price range for $75M biotech IPO | 03-06-13 |
| EC promises $187M for ambitious effort to spawn 200 new rare disease drugs | 03-05-13 |
| AstraZeneca severs ties to Alzheimer's drug from troubled Targacept | 03-05-13 |
| Onyx maps fresh expansion for SF campus | 03-05-13 |
| Theravance: Biotech's big coming-of-age story | 03-05-13 |
| Celgene buys into upstart's new approach to evaluating cancer drugs | 03-05-13 |
| Specialty med price shock rattles ill-equipped payers | 03-05-13 |
| Depomed slams brakes on hot-flash drug after FDA advisers vote to reject | 03-04-13 |
| Vertex touts success with PhII flu drug, scouts collaboration | 03-04-13 |
| Merck KGaA fashions its 6th biotech from Serono R&D wreckage | 03-04-13 |
| J&J, Gilead combo quells hep C in 100% of PhII cohort | 03-04-13 |
| Elan woos investors with a special dividend plan for Tysabri | 03-04-13 |
| Novartis CEO Jimenez focuses R&D on the new blockbuster paradigm | 03-04-13 |
| Celgene's blockbuster dreams fade as apremalist PhIII fails to excite | 03-02-13 |
| FDA staff scrutinizes new hot-flash remedies | 03-01-13 |
| Dutch biotech upstart jumps into high-stakes CETP game with $18.6M raise | 03-01-13 |
| New Optimer Pharma boss reveals details of federal probe of former execs | 03-01-13 |
| Endo names Rajiv De Silva president, CEO | 03-01-13 |
| As sequestration dawns, FDA supporters scramble to ease woes on drug reviews | 03-01-13 |
| Facebook, Google geeks 'hack' into cancer research problem with mobile game | 03-01-13 |
| FDA pins approval on once-monthly version of blockbuster Abilify | 03-01-13 |
| Ablynx raises $40M for R&D work | 02-28-13 |
| Lundbeck gets EU nod for new drug to fight alcohol addiction | 02-28-13 |
| Merck's Tredaptive fiasco blamed on adverse reactions to niacin | 02-28-13 |
| Langer biotech Kala earmarks $11.5M round for next-gen ophthalmology drugs | 02-28-13 |
| Takeda snags rights to lupus drugs from Seattle upstart in $255M deal | 02-28-13 |
| Sarepta spikes on disputed report of adverse events for rival GSK drug | 02-27-13 |
| Optimer seeking buyout offers as CEO is shown the door | 02-27-13 |
| Biosimilars face big delays as blockbuster knockoffs hit a roadblock | 02-27-13 |
| Shionogi wins FDA approval on Osphena for painful sex | 02-27-13 |
| Third Rock's $325M Shire deal was a big win for early-stage investors | 02-27-13 |
| Vertex plots a race through PhIII for "breakthrough" combo CF therapy | 02-26-13 |
| Jazz strikes up a Concert Pharma collaboration on next-gen Xyrem pact | 02-26-13 |
| Roche follows GSK in move to unlock its data vault on drugs | 02-26-13 |
| Januvia, Byetta double pancreatitis risk, JAMA analysis finds | 02-26-13 |
| Leo snags option on oral anti-inflammatory in potential $125M 4SC deal | 02-26-13 |
| Sanofi's Zerhouni, analysts warn sequestration could cripple R&D | 02-26-13 |
| Officials prepare to dismantle patent rules that stifle drug R&D | 02-26-13 |
| Cosmetics group leads $7M round for dermatology upstart Brickell | 02-26-13 |
| AstraZeneca claims PhIII sweep for OIC drug as CV concerns linger | 02-26-13 |
| Cubist grabs option deal to acquire PhII pain drug developer | 02-25-13 |
| Pfizer in push for new R&D drug deals in China | 02-25-13 |
| Intersect nabs $30M for drug/device combo | 02-25-13 |
| Cancer drug developers are blazing a faster, cheaper path to approval | 02-25-13 |
| Merck KGaA reports another R&D setback with PhIII brain cancer failure | 02-25-13 |
| Royalty Pharma offers Elan investors a chance to cash out with $6.55B deal | 02-25-13 |
| Dynavax regroups after FDA turns thumbs down on hep B vaccine Heplisav | 02-25-13 |
| India probes cause of 436 clinical trial deaths | 02-22-13 |
| J&J stakes out Boston/Cambridge HQ for new innovation center | 02-22-13 |
| Report: Booming Genentech plans 600 new hires in 2013 | 02-22-13 |
| Upstart Blaze banks $8.5M A round for new cancer surgery tech | 02-22-13 |
| Roche/Genentech's breakthrough T-DM1 wins blockbuster OK for breast cancer | 02-22-13 |
| Elan lines up biotech deals as it preps for $3B Tysabri windfall | 02-22-13 |
| Ariad lands Jonathan E. Dickinson as general manager, Europe | 02-22-13 |
| Analysts expect blockbuster Tresiba OK--but not soon; Ventrix preps human studies; | 02-21-13 |
| Parents push for data sharing on rare disease drugs | 02-21-13 |
| Repros shares soar after PhIII Androxal study gets back on track | 02-21-13 |
| Investors bankroll unique brains-and-beauty collaboration with $30M round | 02-21-13 |
| Buzz: Shire's new CEO sends mixed signals on 'transformational' M&A strategy | 02-21-13 |
| Ambit joins biotech IPO queue, seeks $58M as AML drug nears PhIII | 02-21-13 |
| Gentium shares wrecked by fresh round of regulatory woes for lead drug | 02-21-13 |
| Report: Buyout buzz grows (again) as InterMune perseveres in PhIII | 02-20-13 |
| Puma's Auerbach revs up PhIII plans after snagging SPA on cancer drug | 02-20-13 |
| Isis earns $7.5M milestone on PhII/III trial launch | 02-20-13 |
| Chelsea rebounds after FDA agrees to take a look at new Northera data | 02-20-13 |
| Star-crossed Merck reorganizes troubled biosimilars effort around Samsung pact | 02-20-13 |
| NC development team nabs $5M angel tranche for its latest biotech play | 02-20-13 |
| MDxHealth hits testing milestone with prostate cancer epigenetic Dx | 02-20-13 |
| Sophiris rolls out $75M IPO to finance PhIII enlarged prostate drug | 02-19-13 |
| Sanofi reports positive PhIII data on oral Gaucher drug | 02-19-13 |
| Gilead races to FDA after hep C blockbuster hopeful scores 4th win in PhIII | 02-19-13 |
| Analysts assign Phytopharm to scrap heap after decisive Parkinson's failure | 02-18-13 |
| Roche grabs rights to Chiasma's PhIII rare disease drug in $595M deal | 02-18-13 |
| Pfizer shuttering CovX research unit in downsizing blitz | 02-16-13 |
| Global CRO Quintiles files to go public | 02-15-13 |
| Pfizer's Xalkori, others spotlight spoils of computer-aided drug discovery | 02-15-13 |
| FDA promises swift review of GSK's blockbuster HIV hopeful | 02-15-13 |
| Blog: AbbVie slams brakes on cancer drug trials after patient death | 02-15-13 |
| Ironwood promotes Mark Currie to president of R&D | 02-15-13 |
| We're taking President's Day off | 02-15-13 |
| GSK's Slaoui talks up 'innovative' late-stage pipeline as regulatory reviews loom | 02-15-13 |
| Biotech benefits from 'breakthrough' guess for its cancer med partnered with J&J | 02-15-13 |
| Japan takes lead in trialing a human stem cell therapy | 02-15-13 |
| Lilly CEO says patent decisions threaten Canadian R&D jobs | 02-14-13 |
| Biocon ties knot with Mylan on 3 blockbuster insulin biosimilar programs | 02-14-13 |
| Biotech startup scores $20M C round for OTC weight-loss product and diabetes med | 02-14-13 |
| Gregoire exits Shire HGT one step ahead of new CEO's debut | 02-14-13 |
| Sanofi rebuilds early-stage R&D strategy in thriving Boston/Cambridge hub | 02-14-13 |
| Third Rock bankrolls immunotherapy upstart with $47M A round | 02-13-13 |
| Tetraphase tees up $86M IPO to back late-stage antibiotics effort | 02-13-13 |
| Bayer, Algeta nab priority review for prostate cancer drug | 02-13-13 |
| Langer's Bind Biosciences raises cash as lead cancer program heads to PhII | 02-13-13 |
| India drags its feet on new drug trials as activists clash in court | 02-13-13 |
| Ziopharm shares spike as PhIII palifosfamide reckoning looms | 02-13-13 |
| J&J, Pharmacyclics score 'breakthrough' coup with blockbuster hopeful ibrutinib | 02-13-13 |
| Early-stage investor Lux targets biotech with new $245M VC fund | 02-13-13 |
| GSK teams with Vanderbilt to rev up trials on new obesity drugs | 02-12-13 |
| Amgen ditches PhIII study plans for bone-healing drug as regulatory bar rises | 02-12-13 |
| StemCells soars after spinal trial gains persist in 2 patients | 02-12-13 |
| Analysts urge AstraZeneca's Soriot to think big on M&A front | 02-12-13 |
| FDA: 'Breakthrough' designation allows for drug approval on PhI data | 02-12-13 |
| The 25 most influential people in biopharma today - 2013 | 02-12-13 |
| Merck ups autoimmune prize to $600M for small Michigan biotech | 02-12-13 |
| U.K.'s e-Therapeutics raises $64M for midstage cancer drug program | 02-11-13 |
| Connecticut consolidation finally over for Pfizer | 02-11-13 |
| Sanofi's move to acquire Regeneron shares triggers market buzz | 02-11-13 |
| Bayer hands off FDA app as pulmonary hypertension drug race heats up | 02-11-13 |
| Spurning panel endorsement, FDA rejects Novo's long-acting insulin Tresiba | 02-11-13 |
| Celgene grabs FDA approval for new multiple myeloma pill | 02-08-13 |
| Analysis: Amgen fighting on both sides of the biosimilars battle | 02-08-13 |
| Cangene drug against bioterrorism toxin likely safe for humans, says FDA | 02-08-13 |
| Oncolytics Biotech surges on lung cancer data | 02-08-13 |
| French biotech rapidly stuck on losing side of hep C revolution | 02-08-13 |
| Pfizer to lop off Asian research unit amid major R&D downsizing | 02-08-13 |
| Jazz CFO joins Medivation's board of directors | 02-08-13 |
| Biotech Tranzyme mulls potential sale after R&D face plants | 02-08-13 |
| A new wave of biotechs takes shape in the U.K. | 02-08-13 |
| FDA to Alzheimer's researchers: Time to focus on very early stage patients | 02-07-13 |
| Amgen highlights late-stage pipeline, biosimilars in growth plan | 02-07-13 |
| Corcept execs enjoy raises in wake of drug OK | 02-07-13 |
| Elan fails to inspire analysts with deal-making plans for $3.25B | 02-07-13 |
| 7 major pharmas unite with academics in ?196M discovery effort | 02-07-13 |
| Tick tock: Lilly scraps RA program as another PhIII drug disappoints | 02-07-13 |
| Report: J&J tops list for most productive pharma company | 02-06-13 |
| Enthralled with pipeline, GSK's Witty targets £1B in annual cost cuts | 02-06-13 |
| Catabasis raises $9M for PhII-ready drug development program | 02-06-13 |
| Ipsen, insolvent biotech partner find buyer for troubled hemophilia drug | 02-06-13 |
| Analysis: Biogen's $3.25 billion Tysabri deal leaves Elan hunting for deals | 02-06-13 |
| Pfizer partner Protalix soars on sale speculation | 02-05-13 |
| GSK boosts trials disclosures sans support from pharma peers | 02-05-13 |
| Portola partners with J&J, Bayer on blood-thinner antidote | 02-05-13 |
| Hemispherx's Ampligen odyssey ends with (another) FDA rejection | 02-05-13 |
| Merck execs struggle with growing uncertainty over late-stage R&D | 02-05-13 |
| Merck Serono nabs an option on late-stage MS therapeutic vax | 02-05-13 |
| Left on FDA 'hold,' Idenix hangs up on once-hot hep C drugs | 02-04-13 |
| Gilead passes two Phase III tests with key hep C pill | 02-04-13 |
| Report: Gamida cites success in leukemia PhIII | 02-04-13 |
| Report on potential NCE threat for Keryx crimps big stock gain | 02-04-13 |
| Bitter setback as TB vaccine fails to protect infants in key study | 02-04-13 |
| Rockwell shares surge as PhIII iron deficiency study offers upbeat outcomes | 02-04-13 |
| Alnylam licenses away hot PCSK9 prospect in 'small' $205M deal | 02-04-13 |
| FDA stamps approval on Hyperion's new orphan drug | 02-01-13 |
| Pfizer offshoot Zoetis enjoys stock surge after IPO | 02-01-13 |
| Gates-backed TB vaccine trial faces moment of truth | 02-01-13 |
| London calling to the bio-world | 02-01-13 |
| Gilead hungers for more cancer drug deals | 02-01-13 |
| Juventas snaps up business development veteran | 02-01-13 |
| GlaxoSmithKline shoots for combo attack against melanoma in surgery patients | 02-01-13 |
| Merck R&D calls for a timeout on osteo blockbuster hopeful | 02-01-13 |
| Bayer spotlights positive PhIII data for fat-busting drug | 02-01-13 |
| Venture firm preps $100M fund for late-stage life sciences investments | 01-31-13 |
| Vanda slides after drug fails PhII/III for depression | 01-31-13 |
| Is AstraZeneca getting ready to buy a pipeline? | 01-31-13 |
| Pharmaxis shares plunge after AdComm rejects new CF drug | 01-31-13 |
| Genentech flashes PhIII progress for prized Rituxan successor | 01-31-13 |
| Pharmaxis suffers FDA committee upset, nabs up to $40M in financing | 01-31-13 |
| Celsion shares routed after PhIII liver cancer study flops | 01-31-13 |
| Amgen, Genzyme race to develop new manufacturing process | 01-30-13 |
| Merck Serono's Geneva staffers find new jobs, found new companies | 01-30-13 |
| FDA staffers frown over Pharmaxis data for inhaled CF treatment | 01-30-13 |
| First biotech IPO of '13 jumps in encouraging debut | 01-30-13 |
| FDA hands Sanofi, Isis an approval for HoFH drug Kynamro | 01-29-13 |
| Boehringer gets FDA panel's thumbs up on 'modest' new COPD treatment | 01-29-13 |
| Biotech billionaire Soon-Shiong unveils 'convergence' cancer drug startup | 01-29-13 |
| Pharmacyclics' success with ibrutinib spawns a rare biotech billionaire | 01-29-13 |
| Ocular Therapeutix scoops up $23.8M to advance eye therapies | 01-29-13 |
| Pfizer on track to chop R&D budget back to $6.5B-$7B range | 01-29-13 |
| Bristol-Myers dumps rights to Lilly's troubled PhIII Erbitux successor | 01-29-13 |
| Genentech plucks rights to Afraxis drug assets in $187M deal | 01-29-13 |
| Amgen, Genentech push blockbuster protection bills in states | 01-29-13 |
| KaloBios plans early test of 2013 market for biotech IPOs | 01-28-13 |
| Is Quintiles plotting a $3B IPO? | 01-28-13 |
| Sanofi CEO Viehbacher boasts of R&D resurgence as FDA takes MS app | 01-28-13 |
| Idenix moves out of FDA limbo with J&J hep C combo pact | 01-28-13 |
| VCs launch another biotech with late-stage R&D model for Big Pharma | 01-28-13 |
| Keryx shares soar on upbeat PhIII results for CKD drug Zerenex | 01-28-13 |
| Takeda grabs long-awaited U.S. approval for diabetes drug Nesina | 01-25-13 |
| Novartis CEO: Don't expect us to slay Vasella's pets | 01-25-13 |
| FDA questions impact of Boehringer's lung drug | 01-25-13 |
